Replies to post #1271 on Dendreon Corp fka DNDNQ

[nerdseeksblonde]

rancher,
if you get a chance try to find my abstract on the
oxidized antigen result posted on Dew's value boad
and the IV DNDN board. What do you think would happen
if DNDN put a bleach in with the fusion protein before
introducting to DC/NK mixture?

I almost got laughed out for suggesting that a little
blonde highlighting may make the protein get noticed
by the immune system a little more easily but the
abstract suggests HOCl eally helps :)

[ocyanblue]

6. I still believe that Dr. Raj Puri of CBER, who has been involved with DNDN since the beginning, will probably be the lead FDA doc. The CTGT panel’s Chair, Dr Mule’, an oncologist and immunologist, who, I believe, worked at the FDA at the time of DNDN’s initial Ph 1 trial, will remain and may have a substantial say in the appointment of any temporary members.

These are safe assumptions. Puri is the the Director of the Tumor Vaccine Division so it would be mighty strange if he is not directly involved in the first vaccine to come up for approval. I was told that the CTGTC was recently renewed for another two year term. Mule' is still listed as its Chair.